<DOC>
	<DOCNO>NCT02332733</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response two dos dengue vaccine ( TV003 ) give 6 month apart healthy adult , adolescent , child Thailand .</brief_summary>
	<brief_title>Evaluating Safety Immune Response Dengue Vaccine ( TV003 ) Healthy Adults , Adolescents , Children Thailand</brief_title>
	<detailed_description>Dengue infection lead cause illness death tropic subtropics . The infection cause one four type dengue virus . This study evaluate safety immunogenicity vaccine ( call TV003 ) four type dengue virus healthy adult , adolescent , child age 12 month 50 year Thailand . Participants enrol sequentially four age group ( adult , adolescent , child , young child ) , researcher evaluate safety data enrol subsequent cohort . Each participant study approximately 12 month . At study entry ( Day 0 ) , participant randomly assign receive either TV003 vaccine placebo vaccine TV003 . All participant receive two dos TV003 placeboâ€”the first dose study entry ( Day 0 ) second dose 6 month later Day 180 . Additional study visit occur Days 6 , 9 , 12 , 15 , 28 , 56 , 72 , 186 , 189 , 192 , 195 , 208 , 236 , 252 , 360 . All study visit include medical history review physical exam . Select study visit also include blood collection urine pregnancy test participant childbearing potential . At vaccination study visit , participant remain clinic approximately 30 minute vaccination observation monitoring . For 20 day vaccination , participant take temperature record symptom . Throughout entire study period , study researcher monitor participant suspect dengue infection .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female participant age 12 month 50 year time enrollment study Residence within great Bangkok area entire duration study period access transportation study site Participants and/or parents/guardians investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit ) Participants remain available duration study , approximately 26 week postsecond vaccination Good general health determine physical examination , laboratory screening , review medical history If participant minor , assent form ( participant age 717 year ) inform consent form sign date minor participant 's parent ( ) legally acceptable representative , respectively . If participant 18 year age old , informed consent form sign date participant ( independent witness require local regulation ) If participant female , must nonchildbearing potential ( i.e. , either premenarcheal , surgically sterilize , one year postmenopausal ) , , childbearing potential , must abstinent use adequate contraceptive precaution ( i.e. , intrauterine contraceptive device , condom spermicide combination , oral contraceptive equivalent hormonal contraception [ e.g. , progestin implantable , cutaneous hormonal patch , injectable contraceptive ] ) 30 day prior vaccination , negative pregnancy test prior vaccination , must agree continue precaution 60 day completion vaccination series . Any child begin menarche study period must follow precaution list , menarche 60 day second vaccine dose . Pregnant lactate female female planning become pregnant planning discontinue abstinence contraceptive precaution Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal , autoimmune , hematologic , endocrine disease functional defect , determine history , physical examination , screen test History neurological , psychiatric , behavioral disorder seizure , exception single febrile seizure childhood Selfreported suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent , great equal 0.5 mg/kg/day 20 mg/day , 2 consecutive week within past 3 month ) . Inhaled topical steroid allow . Body weight less 10 kg time enrollment HIV infection screen confirmatory assay , hepatitis C virus ( HCV ) infection screen confirmatory assay , hepatitis B virus ( HBV ) infection hepatitis B surface antigen ( HBsAg ) screen Screening laboratory value Grade 1 absolute neutrophil count ( ANC ) , alanine aminotransferase ( ALT ) , platelet count , define protocol History allergic disease/reaction likely exacerbate component vaccine ; history severe allergic reaction anaphylaxis Current alcohol abuse drug addiction might interfere ability comply trial procedure Any condition opinion investigator would jeopardize safety right participant trial would render participant unable comply protocol Planned administration vaccine foreseen study protocol , period start 30 day dose study vaccine end 30 day dose ; exception standard infant child inactivate vaccine inactivate influenza vaccine inactivate rabies vaccine ( without administration immunoglobulin ) administer adult child Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine/placebo plan use time study period Administration immunoglobulins and/or blood product within 90 day precede first dose plan administration time study period , might interfere assessment immune response A plan anticipate move location prohibit participate trial full 12 month duration Potential adult participant parent potential child participant , easy access fix mobile telephone Any participant identify site employee investigator study clinic , direct involvement propose study study direction investigator study clinic , well family member ( i.e. , immediate , husband , wife child , adopt natural ) clinic employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>